{"id":"interferon-gamma-recombinant","safety":{"commonSideEffects":[{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Myalgia"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Injection site reactions"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Interferon-gamma (IFN-γ) is a cytokine produced by T cells and natural killer cells that acts as a key regulator of innate and adaptive immunity. It binds to interferon-gamma receptors on immune cells, particularly macrophages, enhancing their microbicidal and tumoricidal activity. The recombinant form is used therapeutically to augment immune responses in conditions characterized by immune deficiency or dysregulation.","oneSentence":"Recombinant interferon-gamma activates macrophages and enhances immune cell function to boost the body's antiviral and antimicrobial defenses.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:16:31.145Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic granulomatous disease"},{"name":"Severe malaria infection"}]},"trialDetails":[{"nctId":"NCT00569127","phase":"PHASE3","title":"Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2007-12-01","conditions":"Colorectal Neuroendocrine Tumor G1, Gastric Neuroendocrine Tumor G1, Neuroendocrine Neoplasm","enrollment":427},{"nctId":"NCT06381661","phase":"PHASE2","title":"Adaptive Platform Trial for Personnalisation of Sepsis Treatment in Children and Adults: a Multi-national, Treatable Traits-guided, Adaptive, Exploratory, Bayesian Basket Trial","status":"NOT_YET_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2026-05-01","conditions":"Sepsis","enrollment":2000},{"nctId":"NCT06694740","phase":"PHASE2, PHASE3","title":"Effect of Interferon Gamma as a Treatment for Post-aggressive Immunosuppression in Intensive Care Units, a Randomized Bayesian Double-blind Controlled Trial Versus Placebo","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2026-01-12","conditions":"Post-aggressive Immunosuppression, Adult Patients Admitted to Intensive Care With Initial Severity (SOFA of the First 24 Hours Post-admission ≥ 6, Adult Under Mechanical Ventilation, and Presenting an mHLA-DR Less Than 8,000AB/C","enrollment":170},{"nctId":"NCT05843786","phase":"PHASE3","title":"Human Recombinant Interferon Gamma in the Treatment of Ventilator-acquired Pneumonia in ICU Patients","status":"RECRUITING","sponsor":"Hospices Civils de Lyon","startDate":"2023-06-30","conditions":"Pneumonia, Ventilator-Associated","enrollment":132},{"nctId":"NCT06529731","phase":"PHASE2","title":"Interferon-γ (IFN-γ) With Donor Leukocyte Infusion to Treat Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndromes Post Allogeneic Hematopoietic Stem Cell Transplantation","status":"RECRUITING","sponsor":"Sawa Ito, MD","startDate":"2024-09-23","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndromes","enrollment":45},{"nctId":"NCT02143518","phase":"PHASE1","title":"Safety and Immunogenicity Study of Na-GST-1 With or Without CpG","status":"COMPLETED","sponsor":"Baylor College of Medicine","startDate":"2014-10","conditions":"Hookworm Infection, Hookworm Disease","enrollment":24},{"nctId":"NCT04418219","phase":"PHASE1, PHASE2","title":"Breast Cancer Vaccine in Combination With Pembrolizumab for Treatment of Persistent, Recurrent, or Metastatic Breast Cancer","status":"WITHDRAWN","sponsor":"Thomas Jefferson University","startDate":"2020-12-21","conditions":"Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Prognostic Stage IV Breast Cancer AJCC v8","enrollment":""},{"nctId":"NCT03747484","phase":"PHASE1, PHASE2","title":"Gene-Modified Immune Cells (FH-MCVA2TCR) in Treating Patients With Metastatic or Unresectable Merkel Cell Cancer","status":"TERMINATED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2019-07-03","conditions":"Other Skin","enrollment":7},{"nctId":"NCT04979052","phase":"PHASE2","title":"Safety and Efficacy of Interferon-Gamma 1b in Patients With Candidemia","status":"RECRUITING","sponsor":"Radboud University Medical Center","startDate":"2022-03-31","conditions":"Candidemia","enrollment":200},{"nctId":"NCT05054114","phase":"NA","title":"Study of the Use of Nasal IFN-γ in Patients for the Prevention of Acute Respiratory Viral Infections, Icluding COVID-19","status":"COMPLETED","sponsor":"SPP Pharmaclon Ltd.","startDate":"2020-12-21","conditions":"COVID-19 Respiratory Infection, Acute Respiratory Disease","enrollment":630},{"nctId":"NCT05065905","phase":"PHASE1, PHASE2","title":"Study of Interferon-Gamma in the Complex Treatment of Patients Infected With HIV and Tuberculosis","status":"COMPLETED","sponsor":"SPP Pharmaclon Ltd.","startDate":"2006-01-19","conditions":"HIV Coinfection, Aids/Hiv Problem, Tuberculosis, Pulmonary","enrollment":78},{"nctId":"NCT04523246","phase":"EARLY_PHASE1","title":"Training the Innate Immune System Against SARS-CoV-2 (COVID-19) Using the Shingrix Vaccine in Nursing Home Residents","status":"COMPLETED","sponsor":"University of Oklahoma","startDate":"2020-09-01","conditions":"Herpes Zoster, Allergy and Immunology, Corona Virus Infection","enrollment":217},{"nctId":"NCT06118619","phase":"","title":"A Multicenter Clinical Trial of Ingaron in Pulmonary Tuberculosis","status":"UNKNOWN","sponsor":"SPP Pharmaclon Ltd.","startDate":"2022-06-01","conditions":"Respiratory Tuberculosis","enrollment":350},{"nctId":"NCT03063632","phase":"PHASE2","title":"Testing the Combination of Two Experimental Drugs MK-3475 (Pembrolizumab) and Interferon-gamma for the Treatment of Mycosis Fungoides and Sézary Syndrome and Advanced Synovial Sarcoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2017-12-14","conditions":"Metastatic Myxoid Liposarcoma, Metastatic Round Cell Liposarcoma, Metastatic Synovial Sarcoma","enrollment":28},{"nctId":"NCT04239313","phase":"PHASE1","title":"A Phase Ib Study of the Recombinant Mycobacterium Tuberculosis Vaccine Freeze-dried (AEC/BC02)","status":"COMPLETED","sponsor":"Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.","startDate":"2020-05-27","conditions":"Tuberculosis","enrollment":30},{"nctId":"NCT05359315","phase":"","title":"Study on the Use of Interferon Gamma (Ingaron) Injections in Patients With Drug-resistant Pulmonary Tuberculosis","status":"UNKNOWN","sponsor":"SPP Pharmaclon Ltd.","startDate":"2022-04-15","conditions":"Pulmonary Tuberculosis","enrollment":84},{"nctId":"NCT05395702","phase":"NA","title":"Study of Ingaron's Effect on Efficacy and Resistance to Antibiotics in Community-acquired Pneumonia","status":"COMPLETED","sponsor":"SPP Pharmaclon Ltd.","startDate":"2017-05-12","conditions":"Community-acquired Pneumonia","enrollment":114},{"nctId":"NCT05386459","phase":"","title":"Study of the Use of the Drug Ingaron in Patients With COVID-19","status":"COMPLETED","sponsor":"SPP Pharmaclon Ltd.","startDate":"2020-04-21","conditions":"COVID-19 Respiratory Infection, Viral Pneumonia","enrollment":36},{"nctId":"NCT05386446","phase":"","title":"Study of the Use of the Ingaron in Volunteers for the Prevention of COVID-19","status":"COMPLETED","sponsor":"SPP Pharmaclon Ltd.","startDate":"2020-04-23","conditions":"COVID-19 Respiratory Infection","enrollment":100},{"nctId":"NCT05378646","phase":"PHASE3","title":"Efficiency and Safety of the Drug Ingaron (Interferon-gamma Human Recombinant) in the Treatment of Chronic Prostatitis","status":"COMPLETED","sponsor":"SPP Pharmaclon Ltd.","startDate":"2009-01-29","conditions":"Chronic Prostatitis","enrollment":30},{"nctId":"NCT03026972","phase":"PHASE1","title":"A Phase ⅠStudy of the Recombinant Mycobacterium Tuberculosis Vaccine Freeze-dried","status":"COMPLETED","sponsor":"Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.","startDate":"2018-04-16","conditions":"Tuberculosis","enrollment":25},{"nctId":"NCT04793568","phase":"PHASE2","title":"Human Recombinant Interferon Gamma-1b for the Prevention of Hospital-acquired Pneumonia in Critically Ill Patients: a Double-blind, International, Phase 2, Randomized, Placebo-controlled Trial - the PREV-HAP Study","status":"UNKNOWN","sponsor":"Nantes University Hospital","startDate":"2021-03-29","conditions":"Critically Ill Patients","enrollment":109},{"nctId":"NCT05156541","phase":"PHASE3","title":"Study of the Efficacy and Safety of the Drug Ingaron (Interferon-gamma) in the Treatment of Anogenital Warts","status":"COMPLETED","sponsor":"SPP Pharmaclon Ltd.","startDate":"2009-05-18","conditions":"Human Papillomavirus Infection, Anogenital Warts","enrollment":30},{"nctId":"NCT00001112","phase":"PHASE1","title":"The Safety and Effectiveness of Injections of Human Recombinant Interferon-gamma in Patients With AIDS Who Have Taken Zidovudine","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":5},{"nctId":"NCT00001004","phase":"PHASE2","title":"A Study of Tumor Necrosis Factor and Human Interferon-gamma in Patients With AIDS Related Complex","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":30},{"nctId":"NCT00000761","phase":"PHASE1","title":"Phase I/II Study of Recombinant Human Interferon-gamma (rIFN-gamma) in HIV-Infected Children","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":20},{"nctId":"NCT00000857","phase":"PHASE1","title":"A Study to Evaluate the Effects of Interleukin-12 (rhIL-12) in HIV-Positive Patients With CD4 Cell Counts Less Than 50 Cells/mm3 or 300-500 Cells/mm3","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":65},{"nctId":"NCT03332225","phase":"PHASE2","title":"A Trial of Validation and Restoration of Immune Dysfunction in Severe Infections and Sepsis","status":"COMPLETED","sponsor":"Hellenic Institute for the Study of Sepsis","startDate":"2017-12-15","conditions":"Sepsis, Macrophage Activation Syndrome","enrollment":36},{"nctId":"NCT00563212","phase":"PHASE1","title":"A Pilot Study of Aerosol Interferon-gamma for Treatment of Idiopathic Pulmonary Fibrosis","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2007-01","conditions":"Pulmonary Fibrosis","enrollment":12},{"nctId":"NCT01957709","phase":"EARLY_PHASE1","title":"Recombinant Interferon Gamma in Treating Patients With Soft Tissue Sarcoma","status":"TERMINATED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2013-09-25","conditions":"Myxoid Liposarcoma, Round Cell Liposarcoma, Synovial Sarcoma","enrollment":8},{"nctId":"NCT02550678","phase":"PHASE1, PHASE2","title":"A Study of the Efficacy and Safety of ASN-002 in Adult Patients With Low-risk Nodular Basal Cell Carcinoma","status":"COMPLETED","sponsor":"Ascend Biopharmaceuticals Ltd","startDate":"2015-09","conditions":"Basal Cell Nevus Syndrome, Skin Neoplasm, Nodular Basal Cell Carcinoma of Skin","enrollment":16},{"nctId":"NCT01649921","phase":"PHASE3","title":"The Effects of Interferon-gamma on Sepsis-induced Immunoparalysis","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2012-11","conditions":"Sepsis, Septic Shock","enrollment":4},{"nctId":"NCT00003414","phase":"PHASE3","title":"Graft-Versus-Host Disease in Treating Patients With Recurrent or Refractory Lymphoma or Hodgkin's Disease","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"1997-10","conditions":"Graft Versus Host Disease, Lymphoma","enrollment":50},{"nctId":"NCT00006113","phase":"PHASE2","title":"Vaccine Therapy Followed by Biological Therapy in Treating Patients With Stage III or Stage IV Melanoma","status":"TERMINATED","sponsor":"University of Southern California","startDate":"1999-06","conditions":"Melanoma (Skin)","enrollment":25},{"nctId":"NCT00024271","phase":"PHASE2","title":"Surgery, Chemotherapy, and Radiation Therapy in Treating Patients With Peritoneal Cancer","status":"UNKNOWN","sponsor":"Herbert Irving Comprehensive Cancer Center","startDate":"2001-05","conditions":"Malignant Mesothelioma","enrollment":""},{"nctId":"NCT00002599","phase":"PHASE3","title":"Combination Chemotherapy and Interferon Alfa With or Without Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Myeloma","status":"UNKNOWN","sponsor":"Medical Research Council","startDate":"1994-09","conditions":"Multiple Myeloma and Plasma Cell Neoplasm","enrollment":750},{"nctId":"NCT00070187","phase":"PHASE2, PHASE3","title":"Immunotherapy Using Cyclosporine, Interferon Gamma, and Interleukin-2 After High-Dose Myeloablative Chemotherapy With Autologous Stem Cell Transplantation in Treating Patients With Refractory or Relapsed Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2003-11","conditions":"Lymphoma","enrollment":24},{"nctId":"NCT00002475","phase":"PHASE2","title":"Cyclophosphamide Plus Vaccine Therapy in Treating Patients With Advanced Cancer","status":"COMPLETED","sponsor":"St. Vincent Medical Center - Los Angeles","startDate":"1991-04","conditions":"Breast Cancer, Colorectal Cancer, Kidney Cancer","enrollment":40},{"nctId":"NCT00002637","phase":"PHASE1, PHASE2","title":"Biological Therapy in Treating Patients With Prostate Cancer","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"1995-01","conditions":"Prostate Cancer","enrollment":25},{"nctId":"NCT00059878","phase":"PHASE2","title":"Voriconazole With or Without Interferon Gamma in Treating Patients With Aspergillosis or Other Fungal Infections","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2003-08","conditions":"Infection, Unspecified Adult Solid Tumor, Protocol Specific","enrollment":""},{"nctId":"NCT00004016","phase":"PHASE1","title":"Interferon Gamma in Treating Patients With Recurrent or Metastatic Melanoma or Other Solid Tumors","status":"COMPLETED","sponsor":"University of Rochester","startDate":"1999-04","conditions":"Melanoma (Skin), Unspecified Adult Solid Tumor, Protocol Specific","enrollment":""},{"nctId":"NCT00008203","phase":"PHASE3","title":"Comparison of Biological Therapies Following Combination Chemotherapy and Bone Marrow or Peripheral Stem Cell Transplantation in Women With Stage II or Stage III Breast Cancer","status":"COMPLETED","sponsor":"Herbert Irving Comprehensive Cancer Center","startDate":"1996-05","conditions":"Breast Cancer","enrollment":""},{"nctId":"NCT00002796","phase":"PHASE1, PHASE2","title":"Phase I-II Study of Fluorouracil in Combination With Phenylbutyrate in Advanced Colorectal Cancer","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"1997-05","conditions":"Mucinous Adenocarcinoma of the Colon, Mucinous Adenocarcinoma of the Rectum, Recurrent Colon Cancer","enrollment":46},{"nctId":"NCT00004032","phase":"PHASE1","title":"Tumor Vaccine and Interferon Gamma in Treating Patients With Refractory Epithelial Ovarian Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"1997-10","conditions":"Recurrent Ovarian Epithelial Cancer","enrollment":12},{"nctId":"NCT00002761","phase":"PHASE1, PHASE2","title":"Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous Leukemia","status":"WITHDRAWN","sponsor":"Columbia University","startDate":"1996-02","conditions":"Leukemia","enrollment":""},{"nctId":"NCT01270490","phase":"PHASE3","title":"Efficacy of Interferon-gamma in Combination With Anidulafungin for the Treatment of Candidemia","status":"UNKNOWN","sponsor":"Radboud University Medical Center","startDate":"2011-01","conditions":"Candidemia","enrollment":20},{"nctId":"NCT00616720","phase":"PHASE2","title":"Interferon-gamma or Aldesleukin and Vaccine Therapy in Treating Patients With Multiple Myeloma","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2001-08","conditions":"Multiple Myeloma and Plasma Cell Neoplasm","enrollment":15},{"nctId":"NCT00002505","phase":"PHASE2","title":"Tumor Cell Vaccine in Treating Patients With Advanced Cancer","status":"COMPLETED","sponsor":"Hoag Memorial Hospital Presbyterian","startDate":"1992-08","conditions":"Unspecified Adult Solid Tumor, Protocol Specific","enrollment":""},{"nctId":"NCT00012467","phase":"PHASE2","title":"Safety and Antifungal Activity of Recombinant Interferon-Gamma 1b (rIFN-Gamma 1b) Given With Standard Therapy in Patients With Cryptococcal Meningitis","status":"COMPLETED","sponsor":"InterMune","startDate":"2000-01","conditions":"Meningitis, Cryptococcal, HIV Infections","enrollment":60},{"nctId":"NCT00007163","phase":"PHASE1","title":"Monoclonal Antibody Treatment of Crohn's Disease","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2000-12","conditions":"Crohn's Disease","enrollment":40},{"nctId":"NCT00001317","phase":"PHASE4","title":"A Phase IV Study of Recombinant Human Gamma Interferon in Patients With Chronic Granulomatous Diseases of Childhood","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"1992-05","conditions":"Chronic Granulomatous Disease","enrollment":100},{"nctId":"NCT00076635","phase":"PHASE3","title":"An Open-Label Study of the Safety of Interferon Gamma-1b in Patients With IPF","status":"TERMINATED","sponsor":"InterMune","startDate":"2003-11","conditions":"Idiopathic Pulmonary Fibrosis, Pulmonary Fibrosis, Lung Disease","enrollment":91},{"nctId":"NCT00052052","phase":"PHASE2","title":"An Open-Label Study of the Safety and Efficacy of Subcutaneous Recombinant Interferon-Gamma 1b (IFN-Gamma 1b) in Patients With Idiopathic Pulmonary Fibrosis (IPF)","status":"COMPLETED","sponsor":"InterMune","startDate":"2002-09","conditions":"Lung Disease, Pulmonary Fibrosis","enrollment":210},{"nctId":"NCT00047645","phase":"PHASE3","title":"A Study of the Safety and Efficacy Interferon-Gamma 1b in Patients With Idiopathic Pulmonary Fibrosis (IPF)","status":"COMPLETED","sponsor":"InterMune","startDate":"2000-04","conditions":"Idiopathic Pulmonary Fibrosis","enrollment":330},{"nctId":"NCT00148863","phase":"PHASE2","title":"Interferon Gamma With Peg-Interferon Alpha 2a and Ribavirin in Non Responders Patients With Chronic Hepatitis C","status":"COMPLETED","sponsor":"French National Agency for Research on AIDS and Viral Hepatitis","startDate":"2004-06","conditions":"Hepatitis C, Chronic","enrollment":65},{"nctId":"NCT00332930","phase":"PHASE1, PHASE2","title":"ITV Extension Study","status":"COMPLETED","sponsor":"Kirby Institute","startDate":"2002-09","conditions":"HIV","enrollment":35},{"nctId":"NCT00002037","phase":"NA","title":"Evaluation of the Therapeutic Benefit of r-metHuIFN- Gamma in AIDS Patients With Disseminated Mycobacterium Avium-Intracellulare (MAI) Infection: A Multi-Centered Pilot Study","status":"COMPLETED","sponsor":"Amgen","startDate":"","conditions":"Mycobacterium Avium-Intracellulare Infection, HIV Infections","enrollment":15},{"nctId":"NCT00002433","phase":"NA","title":"The Effects of r-metHuIFN-Gamma on the Lungs of Patients With AIDS","status":"COMPLETED","sponsor":"Amgen","startDate":"","conditions":"HIV Infections","enrollment":12}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":6,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Interferon-gamma, Recombinant","genericName":"Interferon-gamma, Recombinant","companyName":"Radboud University Medical Center","companyId":"radboud-university-medical-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Recombinant interferon-gamma activates macrophages and enhances immune cell function to boost the body's antiviral and antimicrobial defenses. Used for Chronic granulomatous disease, Severe malaria infection.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}